Described herein are compounds that reduce the production of trimethylamine-N-oxide (TMAO) in a subject, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of a kidney disease or a cardiovascular disease.
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
Provided herein are compositions, systems, kits, and methods for treating glial scarring caused by injury to a central nervous system (CNS) site by administering a CSPG reduction peptide (CRP), or a nucleic acid sequence encoding the CRP. In particular embodiments, CNS site is the result of a stroke in a subject (e.g., human subject that has had a stroke). In certain embodiments, the CRP is composed of a cell membrane penetrating domain, a lysosome targeting domain, and a chondroitin sulfate proteoglycan (CSPG) binding domain.
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
Provided herein are compositions, systems, kits, and methods for treating a patient with a disease or condition by administering nanoparticles comprising a biocompatible polymer, wherein the nanoparticles fully, or almost fully, encapsulate: i) tissue-type plasminogen activator (tPA), ii) at least one antioxidant enzyme selected from: superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, and optionally iii) plasmin protein. In certain embodiments, the disease or condition is selected from: thromboembolism, ischemia-reperfusion injury, stroke, spinal cord injury (SCI), Alzheimer's disease, Muscular Dystrophy, Hypercoagulability, Vaso-occlusive conditions, a fibrotic condition, internal tissue scarring, peritoneal scarring, wound associated scarring, surgical incision associated scarring, and/or dermal scarring.
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
Disclosed is a kinetic perimetry device. The kinetic perimetry device includes a base plate having a first light guide, an actuator movable relative to the base plate and including a second light guide, and a focal aperture that passes through the base plate. The second light guide cooperates with the first light guide to define a window at a point of intersection therebetween. A location of the window relative to the focal aperture is adjustable by moving the actuator relative to the base plate.
A61B 3/024 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour la détermination du champ de vision, p. ex. périmètres
6.
METHODS OF TREATMENT FOR OPIOID-INDUCED VENTILATORY DEPRESSION AND MUSCLE RIGIDITY
Disclosed herein are methods for treating opioid induced conditions, particularly methods are disclosed for treating opioid-induced respiratory depression and muscle rigidity (e.g., chest wall rigidity), for example as a result of opioid exposure or administration.
One or more computing devices, systems and/or methods are provided. In an example, one or more images may be received. A biological object segmentation model may analyze the one or more images to generate a biological object map indicative of regions, of the specimen, including biological objects. Sets of features associated with the biological objects may be determined based upon the biological object map. Scores associated with the biological objects may be determined. One or more target regions of the specimen may be determined based upon the scores.
G06T 7/136 - DécoupageDétection de bords impliquant un seuillage
G06T 7/246 - Analyse du mouvement utilisant des procédés basés sur les caractéristiques, p. ex. le suivi des coins ou des segments
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p. ex. de l'haleine
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
A61B 5/097 - Dispositifs pour faciliter la collecte du gaz respiré ou pour le diriger vers ou à travers des dispositions de mesure
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
Disclosed is a count and capture system (100) for surgical implements. The count and capture system (100) includes a base station (102) having a camera (112) and a cartridge (104) configured to removably engage with the base station (102). The cartridge (104) has an opening (118) configured to receive a surgical implement deposited therein and an aperture (120) spaced from the opening (118). When the cartridge (104) is engaged with the base station (102), the camera (112) has a field of view into an interior of the cartridge (104) through the aperture (120). The count and capture system (100) further includes means for transporting the surgical implement within the cartridge (104) from a first location adjacent the opening to a second location aligned with the camera (112).
A61B 50/36 - Récipients spécialement adaptés à l'emballage, la protection, la distribution, la collecte ou l'élimination des appareils ou des instruments chirurgicaux ou de diagnostic pour la collecte ou l'élimination des articles usagés
A61B 50/20 - Équipements de support spécialement adaptés aux appareils ou aux instruments chirurgicaux ou de diagnostic
10.
COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION
Disclosed herein are compounds, pharmaceutical compositions, and methods for treating disorders such as heart failure by restoring β-adrenergic receptor function.
Provided herein are compositions, systems, kits, and methods for reducing chemoresistance (e.g., to platinum containing chemotherapeutics) and treating certain diseases, using nucleic acid sequences (e.g., aptamers and antisense sequences) that bind to certain mRNAs (e.g., WTAP), or bind a SEFIR domain of an ACT1 protein, or bind to or inhibit mRNA sequences that bind to Act1 protein.
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
An abdominal -wall retractor includes a mounting armature affixed stationary relative to or near an operating table. The retractor includes an upward tensioning rail affixed to the mounting armature. An upward tension linkage can engage the upward tension rail and provide tension between the upward tensioning rail and an upward surgical tool affixed to an incision site of the patient. The mounting armature includes one or more arms to elevate and position the upward tensioning rail in a fixed position above a surgical site in order to retract an abdominal wall upward at an angle from the horizontal via the supplied tension in the upward tension linkage during a surgical procedure. A lateral retraction rail can be positioned on the mounting armature below the upward tension rail. A lateral tension linkage with a lateral surgical tool can engage the lateral retraction rail to provide lateral retraction to the abdominal wall.
Certain embodiments of the present application relate to a catheter assembly for augmenting separation between the parietal and visceral pericardium of a patient's heart. The catheter assembly generally includes an outer catheter, an inner catheter, and a balloon. The outer catheter includes a first lumen and a second lumen, and an aperture in a wall of the outer catheter is in fluid communication with the second lumen. The inner catheter is operable to be received and translated within the first lumen of the outer catheter, and the inner catheter comprises a radiofrequency emitter tip adapted to emit radiofrequency energy. The balloon is sealed to an external surface of the outer catheter, and an interior of the balloon is in fluid communication with the second lumen via the aperture such that the balloon is operable to be inflated via the second lumen.
A61B 18/12 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par chauffage en faisant passer des courants à travers les tissus à chauffer, p. ex. des courants à haute fréquence
A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
Provided herein are systems, kits, compositions, and methods for treating a subject with cancer or other disease with a CAR T-cell (or other immune cell) that has at least one endogenous gene that is modulated, and/or wherein mRNA from the gene is over-expressed or under-expressed, or that has exogenous mRNA that is expressed (e.g., expressed by an expression vector, or comprising modified bases). In certain embodiments, the endogenous gene, or mRNA therefrom, is inhibited or silenced and is selected from Table 2 (e.g., selected from PCNX1, PDCD10, MYC, ASXL1, RPTOR, BCAP31, ANKRD11, TCF3, IQCB1, CTLA4, ZZEF1, SRCAP, CARD8, DNMT1 and HSF2). In some embodiments, the endogenous gene, or mRNA therefrom, or mRNA in an expression vector, is over-expressed and is selected from Table 1 (e.g., NOSIP, FADD, RUNX1, AQR, ATE1, ATP9B, LSM2, CD3D, WNK1, EIF2B3, and TAL2).
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
15.
SYSTEM AND METHOD FOR DOSE ACCUMULATION DETERMINATION AND PATIENT PROFILE GENERATION
One or more computing devices, systems and/or methods are provided. In an example, records of treatment sessions of a patient may be collected. Each of the records may be indicative of a time of a treatment session and a dose parameter of a dose administered to the patient in the treatment session. A dose accumulation level of the patient may be determined based upon times and dose parameters indicated by the records.
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
16.
AUTOMATIC CARDIOVASCULAR MAGNETIC RESONANCE IMAGING
The present disclosure relates to automated cardiovascular magnetic resonance imaging systems and methods that can be used to produce both cine and delayed enhancement images with minimal interaction by a clinician and minimal dependence on system hardware and clinician skill and experience. The images may be acquired during patient free-breathing and does not require a contrast agent. The resulting images be time-resolved three-dimensional images having isotropic resolution, permitting retrospective two-dimensional image reconstruction in any plane image reconstruction according to a retrospectively determined inversion time.
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/567 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne débloquées par des signaux physiologiques
17.
KYNURENINE RESPONSIVE BACTERIA AND CANCER THERAPIES
Provided herein are kits, compositions, systems, and methods for treating a subject with a tumor with kynurenine responsive bacteria (e.g., such that the bacteria reduce or eliminate said tumor). In certain embodiments, the kynurenine responsive bacteria comprise one or more nucleic acid sequences comprising: i) a first nucleotide sequence (e.g., not endogenous to said bacteria) encoding a kynurenine transcriptional regulator protein, and ii) a second nucleotide sequence (e.g., not endogenous to said bacteria or overexpressing an endogenous equivalent protein) encoding a kynurenine transporter protein. In particular embodiments, the kynurenine responsive bacteria further comprise at least one of the following: i) a third nucleotide sequence comprising a kynurenine responsive promoter upstream of a plasmid replication gene encoding a plasmid replication protein, ii) a fourth nucleotide sequence comprising a kynurenine responsive promoter upstream of a reporter gene encoding a reporter protein, and iii) a fifth or more nucleotide sequence comprising a kynurenine responsive promoter upstream of a gene essential for bacterial growth, or a gene codes a for therapeutic payload.
A combinatorial cancer vaccine for cancer therapy includes a lipid nanoparticle that includes a plurality of pH sensitive protonatable or ionizable lipids, at least one of a TLR7 agonist, TLR 8 agonist or a TLR9 agonist complexed with and/or encapsulated by the pH sensitive protonatable or ionizable lipids, optionally a nucleic acid encoding a cancer antigen or neoantigen complexed or conjugated with and/or encapsulated by the pH sensitive protonatable or ionizable lipids, and optionally a stabilizing amount of at least one stabilizing polymer, polyethylene glycol or polysaccharide, or structural lipid that is conjugated to and/or complexed with the pH sensitive protonatable or ionizable lipids.
C07C 229/04 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé
Provided herein are compositions, systems, kits, and methods for using various low concentrations of functionalized fullerenes (e.g., polyhydroxy fullerenes), functionalzied graphene (e.g., graphene oxide), and/or functionalized carbon nanotubes (e.g., carboxylated multiwalled carbon nanotubes), to generate tinted skin care compositions, such as sunscreens and cosmetics, that a user can apply to generally match their skin tone. In certain embodiments, the compositions, kits, and systems herein comprise a dermatologically acceptable carrier (e.g., that is white or light in color prior to being in the composition) and a functionalized fullerene compound, functionalized graphene, and/or functionalized carbon nanotubes, for tinting present at a concentration of about 0.1% (e.g., for very light tan) to about 3.0% (e.g., for very dark brown). In certain embodiments, the compositions herein are present in a container, such as a sunscreen container or makeup container.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (AIST) (Japon)
Inventeur(s)
Sakota, Daisuke
Okamoto, Toshihiro
Abrégé
Provided is a system and method for improving ex vivo heart perfusion in a working mode or a resting mode configuration and for improving in vivo heart perfusion. The system can reduce myocardial energy consumption in a working mode configuration by unloading the perfusate in the left ventricle using a left ventricular assist pump (LVAD) that is synchronized with cardiac function of a heart. Disclosed methods achieve or simulate physiological coronary perfusion in a resting mode configuration, without perfusing the left ventricle, by artificially generating aortic pressure that may be synchronized with cardiac function.
Provided herein are kits, compositions, systems, and methods for treating a subject that is at risk for refeeding syndrome (e.g., a human subject that is starving and about to receive caloric support, or at risk of malnutrition or refeeding syndrome). In some embodiments, the system and kits herein provide a container (e.g., pouch for attaching to a feeding tube, or part of a syringe for feeding) that contains a micronutrient composition that contains thiamine, phosphorous, magnesium, and potassium, wherein the micronutrient composition is optionally substantially free from calories. In particular embodiments, methods herein rapidly replace micronutrients commonly depleted in the malnourished patient (e.g., that are important for tube feeding tolerance).
A drug delivery system is provided and includes an electronic stimulation implant, a drug delivery pump, and a computing device coupled to the electronic stimulation implant and the drug delivery- pump. The electronic stimulation implant is configured to be implanted adjacent to a nerve and/or blood vessel of a subject. The computing device stores instructions that, when executed, causes one or more processors to activate the electronic stimulation implant to deliver stimulation energy to the nerve/blood vessel to modulate a blood brain barrier of the subject to increase its permeability. The processor activates, when instructed, the drug delivery pump to deliver a therapeutic agent to the subject via the blood brain barrier once its permeability has been suitably adjusted. The processor further can instruct the electronic stimulation implant to adjust or cease the first stimulation energy- once drug delivery- is complete to reduce the permeability' of the blood brain barrier.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
23.
CHIMERIC ANTIGEN RECEPTORS WITH A TIP CO-STIMULATORY DOMAIN
Provided herein are systems, kits, compositions, and methods for treating a subject with cancer or other disease with a CAR T-cell expressing a chimeric antigen receptor which comprises a TIP co-stimulatory domain, wherein the TIP co-stimulatory domain comprises a CSKH peptide and/or a SH3 peptide. In certain embodiments, the CAR comprises a binding molecule, transmembrane domain, and an activating domain.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
24.
WEARABLE DEVICE AND SYSTEM FOR HUMAN ACTIVITY RECOGNITION USING TOPOLOGICAL DATA ANALYSIS METHODS
A system for human activity recognition using persistent homology and machine learning includes a wearable device having a sensor configured to detect motion of a subject wearing the wearable device, and a processor configured to receive data from the sensor, generate persistence images of the data using persistent homology, input the persistence images to a machine learning model that classifies the persistence images according to a classification of activity, compare the classified activity with a baseline model, and produce a recognition of the activity of the subject based on the comparison.
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
A system for controlled drainage or delivery of a fluid from or to a patient includes a metering device configured to control a flow of fluid from or to the patient. The metering device includes a housing having a first port connectable to provide communication with a catheter for delivery of fluid to or from the patient and a second port connectable to provide communication with a reservoir for said fluid. A patch is adapted to be affixed to a patient and has a first side configured to face the patient while in-use and a second side opposite the first side. The housing of the metering device may be configured to be attached to the second side of the patch.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
26.
3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
Disclosed herein are compounds that inhibit the function of 3β-hydroxysteroid dehydrogenase (3βHSD1), pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., for the treatment of prostate cancer, breast cancer, and other diseases dependent on the activity of 3βHSD1.
C07D 277/66 - Benzothiazoles avec uniquement des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés en position 2 avec des cycles ou des systèmes cycliques aromatiques liés directement en position 2
A61K 31/428 - Thiazoles condensés avec des carbocycles
Provided herein are compositions, systems, kits, and methods for treating fibronectin-related inflammation and/or fibrosis which, for example, occurs in pain (e.g., neuropathic pain, inflammatory pain, chemotherapy-induced peripheral neuropathy, etc.), nervous system disorders (e.g., stoke, brain injury, spinal cord injury, peripheral nerves injury, etc.), neurodegenerative diseases (e.g., Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, etc.), organ transplantation (e.g., lung, kidney, heart, liver, etc.), lung fibrosis, liver fibrosis, amputation, and cosmetic and plastic surgery applications, in a subject by administering (e.g., subcutaneously) a fibronectin reduction peptide (FRP), or a nucleic acid sequence encoding the FRP, wherein the FRP comprises: i) a cell membrane and blood brain barrier (BBB) penetrating (CMBBBP) motif, ii) a fibronectin binding motif, and iii) a lysosome targeting motif.
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
29.
ECL1 BETA-1 ADRENERGIC RECEPTOR VACCINES, PROTEINS, AND NUCLEIC ACID SEQUENCES
The present invention relates to systems, kits, and methods for treating a subject that has cardiovascular disease or Systemic Sclerosis with at least one of the following: a) a first antigenic protein that elicits the production of anti-ECL1 b1AR antibodies in said subject, b) a second antigenic protein comprising a portion of human b1AR ECL1, or modified portion thereof (e.g., cyclic peptide) linked to a portion of human b1AR ECL2; c) a mixture of an antigenic protein comprising at least a portion of human b1AR ECL1, and an antigenic protein comprising at least a portion of human b1AR ECL2; d) a vector comprising a nucleic acid sequence encoding such antigenic proteins, and g) a mRNA sequence encoding a portion of ECL1 of human b1-Adrenergic Receptor.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
30.
SYSTEM AND METHOD FOR DIAGNOSING INFLAMMATORY BOWEL DISEASE STATE AND SEVERITY
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
31.
METHOD AND APPARATUS FOR COOLING A BODY OF A DONOR
Apparatus and methods for cooling a body of a donor are provided. The cooling apparatus (100) includes a vessel (104) and a pump (112) configured to circulate a fluid through the vessel while a body of a donor is in the vessel. The vessel may be a basin or a bag. The fluid (120) may comprise a first fluid (134) and/or a refrigerant (144). The cooling apparatus may further comprise a controller (130), a fluid temperature controller (112), a fluid composition controller (126) and/or a chest compression device (114).
A surface-mounted device is applied to a surface of a patient. The device includes one or more sensors that generate signals indicative of a contour of that surface. The resulting measured surface contour then can be registered with pre-procedure medical image data. Once registered, a surgical procedure can be guided based on the positional and orientational relationships between the patient's underlying anatomy and the registered surface contour measured by the device.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 90/50 - Supports pour instruments chirurgicaux, p. ex. bras articulés
33.
METHOD AND APPARATUS FOR MEASURING OCULAR SURFACE FRICTION
An apparatus and/or a method for measuring ocular surface friction are provided. In an example, the apparatus may include a strip and/or a measuring device configured to measure the ocular surface friction based upon a position of the strip. The strip may be inserted inside an eyelid of an eye. A strip pulling force may be applied to the strip. The strip pulling force may cause the strip to be released from the eye. The ocular surface friction associated with the eye may be measured based upon a characteristic, of the strip, when the strip is released from the eye.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
34.
MUTATION INDUCED CONFORMATIONAL CHANGES IN MRNA THAT PREVENT OR INDUCE M6A METHYLATION AT DISTAL SITES
The present invention relates to methods, kits, and compositions for testing a sample from a subject and determining: i) if said subject is A/A, A/C, or C/C at position 4444 in the Glutamyl-prolyl-tRNA synthetase 1 (EPRS1) gene or mRNA, and/or ii) if said subject expresses only the 1482T version, only the 1482P version, or both the 1482T and 1482P versions, of the EPRS1 protein; and/or iii) if said subject is m6A methylated or m6A unmethylated at A4355 and/or A4464 in said EPRS1 mRNA; and determining that the subject has hypomyelinating leukodystrophy (HLD) or other neurological condition. The present application also relates to a bioinformatic pipeline to assess if m6A-distal single-nucleotide-variations (m6Ad-SNV) affect methylation of DRACH sites.
The present disclosure relates to anti-ToH1 antibodies, methods of generating anti-ToH1 antibodies, and methods of use of anti-ToH1 antibodies for diagnosis and treatment of microbial disease and/or chronic inflammatory disease, including microbial infection and microbe-associated chronic inflammatory conditions.
11211111ρ dispersion may be used to identify and track tissue parameters (such as osteoarthritis and muscle degeneration) before being expressed in other measurable manners.
G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
38.
3D QUANTITATIVE JOINT MUSCLE EVALUATION VIA AUTOMATED JOINT MUSCLE SEGMENTATION WITH ARTIFICIAL INTELLIGENCE
A muscle segmentation method and system utilizes a trained machine learning system to identify and segment skeletal muscle from input magnetic resonance images of the shoulder. Properties of the muscle can be determined from the segmentation, and clinical treatment decisions can be more accurately made based on the determined properties.
Provided herein are human EIF3L binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human EIF3L binding molecules (e.g., monoclonal antibodies or antigen binding fragments thereof) having particular light and/or heavy chains variable regions, or light chain and/or heavy chain CDRs, and methods for using such molecules, and/or other EIF3L binding molecules, and/or CD63 binding molecules, to treat a prothrombotic condition that is accompanied by pathological exosome production in subjects (e.g., human subjects with tumor-mediated thrombosis). In some embodiments, the presence or level of cancer is detected by detecting CD63 positive, and/or PCA3 positive, and/or EIF3L-positive, exosomes in a sample.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to systems, kits, and methods for identifying subjects with increased or decreased levels (e.g., in plasma) of at least one gut derived aromatic amino acid metabolite (GDAAM), as well as methods of determining the risk of cardiovascular disease, or other diseases, based on such levels. In certain embodiments, the level of at least two of the GDAAMs is employed (e.g., 2, 3, 4 or more). In some embodiments, a subject with altered levels of at least one of the GDAAMs is treated with a CVD therapeutic (e.g., lipid lowering agent) or one that inhibits the TMA/FMO3/TMAO pathway.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
41.
HUMAN FACTOR VII DELETION CONSTRUCTS FOR TREATING CANCER
Provided herein are compositions, kits, and methods for treating a human subject with cancer (e.g., brain cancer) with a composition comprising: a human delta Factor VII construct, or nucleic acid sequence encoding said human delta Factor VII construct. In certain embodiments, the human delta Factor VII construct comprises a Propeptide domain and EGF-1 domain, or portions thereof, and lacks a functioning Peptidase S1 domain. In some embodiments, the human subject has glioblastoma and has been previously treated with radiation therapy.
A head fixation device for an animal subject includes a base for supporting the animal subject and a head fixture fixed to the base, the head fixture defining a cavity for receiving a snout of the animal subject. The head fixation device further includes first and second opposing set screws configured to compressively engage a neck of the animal subject when received in the head fixation device in order to restrain neck movement thereof.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A01K 1/06 - Dispositifs d'attache des animaux, p. ex. licous, garrots, jougs ou chaînes
A61D 3/00 - Appareils pour soutenir ou ligoter les animaux à opérer
43.
SYSTEM AND METHOD FOR SEGMENTATION OF OCULAR AT-RISK AREAS
One or more computing devices, systems and/or methods are provided. In an example, a first ocular image may be evaluated to generate a first segmentation indicative of a first set of ocular zones. The first segmentation may be analyzed to identify a first set of at-risk areas associated with a risk of an eye condition. A risk mask may be generated based upon the first set of at-risk areas. A machine learning model may be trained using the risk mask to generate a trained machine learning model. A set of ocular images of an eye of a person may be received. One or more images of the set of ocular images may be evaluated using the trained machine learning model to generate an at-risk area segmentation identifying a second set of at-risk areas, of the eye, indicative of a risk of one or more eye conditions.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
44.
SYSTEM AND METHOD FOR PATHOLOGIC FEATURE DETECTION AND QUANTIFICATION
One or more computing devices, systems and/or methods are provided. In an example, a set of images of an eye of a person may be identified. The set of images may include an en face optical coherence tomography (OCT) image and an OCT Brightness-scan (B-scan). The en face OCT image may be evaluated using a first machine learning model to generate an en face feature segmentation indicative of one or more areas, of the en face OCT image, corresponding to a first pathological feature. The OCT B-scan may be evaluated using a second machine learning model to generate a B-scan feature segmentation indicative of one or more areas, of the OCT B-scan, corresponding to the first pathological feature. An enhanced pathological feature segmentation indicative of the first pathological feature may be generated based upon the en face feature segmentation and the B- scan feature segmentation.
One or more computing devices, systems and/or methods are provided. In an example, one or more images of an eye of a person may be received. A first machine learning model may be used to generate a first representation indicative of a first ocular zone based upon the one or more images. A second machine learning model may be used to generate a second representation indicative of one or more second ocular zones of the eye based upon the one or more images. An ocular segmentation profile indicative of first segment corresponding to the first ocular zone of the eye may be generated based upon the first representation and/or the second representation.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
An introducer needle assembly includes an inner shaft nested within an outer shaft. The inner shaft is repositionable relative to the outer shaft between a first orientation and a second orientation. In the first orientation, the inner and outer shafts define a window adjacent to a proximal end of the outer shaft that provides access to a common channel defined within the inner and outer shafts. In the second orientation, the inner and outer shafts define a slot that provides access to said common channel. The introducer needle is useful to facilitate a tunneling procedure wherein redirection of the tunneled catheter, for example, occurs entirely subcutaneously.
A system for minimizing nucleation of clot and biofilm material on inner and outer surfaces of a medical tube a hub connector and a mechanical agitator. The hub connector is configured to provide fluid communication between a medical tube and one or more fluid sources when attached thereto. The mechanical agitator is associated with the hub connector and is configured to deliver oscillatory mechanical energy thereto so that the oscillatory mechanical energy further will be delivered substantially uniformly to the medical tube when attached thereto.
A tabular synthetic data generation method comprising generating a plurality of synthetic datasets based on an empirically collected dataset according to a plurality of different models. The plurality of synthetic datasets are scored based on the respective automated machine learning (Auto-ML) analysis of a trained machine learning system based on the generated synthetic data. Identifying an optimal one of the generated synthetic datasets based on the Auto- ML scores. The Auto-ML scores can be based on analysis of machine learning systems trained on the empirically collected dataset, the generated synthetic datasets, and a tertiary ML analysis.
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
49.
GASTROINTESTINAL RETENTIVE FORMULATIONS OF ECHINOCANDINS
Provided herein are methods and compositions for delivering echinocandins (e.g., caspofungin) to a subject to increase retention time in the gastrointestinal tract (e.g., to promote a localized action in the intestinal region and reduced absorption of the echinocandin) after oral administration of the composition. In certain embodiments, the compositions comprise an echinocandin and a carrier agent. In some embodiments, the compositions are used to treat fungal infections and/or inflammatory bowel disease in a subject.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
Provided herein are compositions, systems, kits, and methods for applying a composition topically to a bodily area of a subject that has precancerous and/or cancerous cells (e.g., skin cancer cells) and/or is adjacent to underlying precancerous and/or cancerous cells, where the composition comprises N-phosphonacetyl-L-aspartate (PALA) (aka sparfosic acid) and water, and optionally further comprises at least one non-ionic surfactant.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
Provided herein are human Cluster of Differentiation 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human CD6 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat T-cell related diseases (e.g., cancer, such as T-cell lymphoma). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided herein are human complement component 2 (C2) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human C2 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat complement-related diseases (e.g., dysregulated complement activation diseases). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
An airway navigation method and system comprising of obtaining tracking data from plurality electromagnetic sensors on an airway scope device and a patient, with tracking data relative to a landmark of the patient. Further, the tracking data is used with an airway model to help a clinician navigate the patient's airway. The tracking data and airway model can be displayed to the clinician. The airway model can be an actual model of the patient or an estimated model.
A61B 10/04 - Instruments endoscopiques, p. ex. instruments de type cathéther
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
G01B 7/004 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les coordonnées de points
G06T 19/00 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie
Devices, systems, and methods for treating sleep apnea are disclosed herein. According to some embodiments, the present technology includes an implantable device comprising an electronics package and first and second elongate leads electrically coupled to the electronics package. Each of the first and second leads can comprise (a) a first conductive region configured to be implanted at a first treatment site at an under-chin region of the patient's head, where the first conductive region is configured to deliver a first electrical signal to the first treatment site to thereby activate the genioglossus muscle, and (b) a second conductive region configured to be implanted at a second treatment site at a neck region of the patient, where the second conductive region is configured to deliver a second electrical signal to the second treatment site to thereby activate an infrahyoid strap muscle.
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61F 5/56 - Dispositifs pour prévenir le ronflement
One or more wearable devices, computing devices, systems and/or methods are provided. In an example, a device is provided. The device may include one or more accelerometers configured to generate measurement data based upon movement associated with a body part of a person. The device may include a communication device configured to transmit a message comprising the measurement data to a computing device. The device may be operable within an imaging region of an imaging machine.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
G01R 33/28 - Détails des appareils prévus dans les groupes
G16H 40/00 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux
A burr hole device includes a base defining an opening, wherein the base is fixable to a skull of a subject such that the opening is aligned with a burr hole in the skull. The burr hole device further includes a fluid retainer that is removably coupled to the base and defines a cavity in fluid communication with the opening of the base.
A61B 90/11 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61M 27/00 - Appareillage pour drainage des blessures
58.
POLYOL SWEETENERS AND CARDIOVASCULAR AND THROMBOTIC EVENT RISK
Provided herein are compositions, systems, kits, and methods for determining the level of a polyol sweetener in a biological sample from a subject (e.g., a subject with, or suspected of having, or at increased risk of developing: a cardiovascular disease, a major adverse cardiovascular event, or enhanced thrombosis). In certain embodiments, determining such polyol sweetener levels are higher than a control level allows a subject to be prescribed, or administered, a CVD therapeutic, anti-thrombotic agent, or lifestyle change to reduce consumption of such polyol sweeteners. In certain embodiments, xylitol is detected in a biological sample from a subject such that xylitol's structural isomers arabitol and rabitol are distinguished. In other embodiments, erythritol is detected in a biological sample from a subject such that erythritol's structural isomer threitol is distinguished.
G01N 33/60 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées faisant intervenir des substances marquées radioactives
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A shunt device is manipulable between a collapsed configuration and a shunt configuration. The shunt device includes a shunt frame assembly having a first anchor and a second anchor that are configured to radially flare from the collapsed configuration toward the shunt configuration. The second anchor defines a proximal opening of the shunt device in the shunt configuration, and the first anchor and second anchor define a common central axis. The shunt device further includes a flow director that extends distally from the shunt frame assembly and defines a fluid passageway and a distal opening at an end of the fluid passageway. The flow director is configured to redirect at least some fluid flowing through the fluid passageway such that the at least some fluid is discharged through the distal opening in a fluid direction transverse to the central axis.
A61B 17/11 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour réaliser l'anastomoseBoutons pour anastomose
Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) with a composition i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: SFTS virus Gn and/or Gc envelope glycoprotein, or ii) polynucleotides encoding said fusion proteins (e.g., mRNA sequences present in lipid nanoparticles).
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A system for treating an animal subject includes a first neurostimulator configured to be operatively coupled to a first airway muscle of the subject; a second neurostimulator configured to be operatively coupled to a second airway muscle of the subject; and a controller configured to operate the first neurostimulator and the second neurostimulator in synergy to generate a first electrical stimulus and a second electrical stimulus, respectively.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
63.
FUSION NEOANTIGENS FOR USE IN CANCER VACCINES, ANTIBODY THERAPY, AND CELL THERAPIES
Provided herein are compositions, systems, kits, and methods for treating a patient with cancer (e.g., Ewing's Sarcoma) by treating the patient with at least one of the following compositions: a) a composition comprising at least a portion of at least one fusion neoantigen selected from: EWSR1-FLi1, EWS-FEV, EWSR1-ERG, EWS-ATF, EWS-WT1, PAX7- FOXO1, CCNB3-BCOR, CIC-DVX, SS18-SSX2; b) a composition comprising a nucleic acid sequence encoding said at least a portion of said at least one fusion neoantigen; c) a composition comprising an antibody, or antigen-binding fragment, the specifically binds said at least a portion of said at least one fusion neoantigen; and/or d) a composition comprising a chimeric antigen receptor T-cell (CAR T cell) that expresses a chimeric antigen receptor that is specific for said at least a portion of said at least one fusion neoantigen.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
64.
ACCURATE PREDICTION OF MOLECULAR PROPERTIES AND DRUG TARGETS USING A SELF-SUPERVISED IMAGE REPRESENTATION LEARNING FRAMEWORK
A machine learning system receives, as an input, molecular images or molecular videos and is configured to predict molecular properties (e.g., binding affinities, inhibition constants, inhibitory concentration at 50%, drug metabolism, or the like), predicting anti-viral activities, identifying anti-viral inhibitors, perform like analyses of the input molecules. The machine learning system includes an encoder that extracts latent features of the molecule of the input image or video, and one or more fully connected layers that perform a classification, regression, or clustering of the latent features as the analysis of the molecule. The encoder is pre-trained according to various tasks, and the fully connected layer is fine-tuned according to the desired analysis.
The present invention provides compositions, systems, and methods for treating or preventing brain disorder with compositions comprising a prebiotic (e.g., green banana flour) and one or both of Lactobacillus reuteri, and Lactobacillus plantarum. In certain embodiments, the brain disorder is selected from neuroinflammation, a neurological disorder, a neuropsychiatric disorder, and a behavioral disorder. In some embodiments, the prebiotic, Lactobacillus reuteri, and Lactobacillus plantarum are provided as a powder inside an ingestible capsule.
Provided herein are extra-cellular domain Mullerian hormone receptor type II (AMHR2-ED) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are AMHR2-ED binding molecules (e.g., monoclonal antibodies or antigen binding fragments thereof) with particular light and/or heavy chains variable regions (SEQ ID NOs:12, 17, 22, or 27), or light chain and/or heavy chain CDRs (e.g., selected from SEQ ID NOS:13, 14, 15, 18, 19, and 20) and methods for using such molecules to treat ovarian and/or endometrial cancers.
A valve assembly for controlled drainage or delivery of a fluid from or to a patient including an outlet, an inlet, a diaphragm chamber and a diaphragm dividing the diaphragm chamber into a first chamber cavity and a second chamber cavity. The diaphragm being deflectable toward a first wall of the diaphragm chamber wherein the first chamber cavity contracts and the second chamber cavity expands, and oppositely toward a second wall of the diaphragm chamber wherein the second chamber cavity contracts and the first chamber cavity expands. A plunger is translatable between a first actuation state that establishes fluid communication between the outlet and the second chamber cavity, and separately between the inlet and the first chamber cavity. The valve also having a second actuation state that establishes fluid communication between the outlet and the first chamber cavity, and separately between the inlet and the second chamber cavity.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
69.
ENHANCED STOCK STENTS BASED ON POPULATION MODELING OF TUBULAR ANATOMICAL STRUCTURES
Technologies as described herein are directed towards generating optimized stent designs for treatment of tubular anatomical structures. In an exemplary computing system, the system obtains imaging data comprising images representative of anatomical structures. The system then generates a plurality of models based upon the imaging data. The models are then clustered based upon similar characteristics of the models. Certain fit parameters are applied to the models in each cluster and an optimized stent shape is generated for each cluster, wherein each optimized stent shape is representative of the models within the cluster.
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
A portable, patient-wearable perfusion system includes a patch configured to cover at least a portion of a biological tissue graft implanted within a defect in a patient, a perfusion assembly configured to be worn or carried on the patient, and arterial and venous cannulas. The arterial and venous cannulas are configured to yield a closed fluid circuit for the perfusate to circulate through the graft. The patch includes a first sensor for detecting a first parameter relating to a physiologic state of the biological tissue graft. The perfusion assembly includes a reservoir for a perfusate, a pump, and a controller operatively coupled to the sensor. The controller is configured to operate the pump to control the physiologic state of the tissue graft based on data regarding the first parameter. The portable-patient wearable perfusion system may be used to preserve the implanted graft until the body naturally vascularizes the graft.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
An introducer includes an introducer body having longitudinally spaced proximal and distal introducer ends. The introducer body has laterally spaced inner and outer introducer walls. The inner introducer wall defines an introducer lumen. At least one aperture extends laterally through the introducer body between the inner and outer introducer walls to place the introducer lumen in fluid communication with an ambient space therethrough.
A61M 25/06 - Aiguilles avec un guide pour piquer le corps ou analogues
A61M 29/00 - Dilatateurs avec ou sans moyens pour introduire des agents, p. ex. des remèdes
A61M 39/06 - Soupapes hémostatiques, c.-à-d. éléments formant joint autour d'une aiguille, d'un cathéter ou similaire, et se fermant après leur retrait
A method of treating an animal subject includes applying a nerve interface to a muscle pedicle of the subject, the muscle pedicle having a peripheral nerve inserted therein, wherein the nerve interface is configured to provide electrical communication between the peripheral nerve and an electronic device.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A filter adapter including a housing having a first filter port and a second filter port, a first hose port configured to connect to a first hose, a second hose port configured to connect to a second hose, a first access port and a second access port. A shuttle gate is disposed in the housing and is configured to move between a first position wherein one of the first filter port and the first hose port is placed in fluid communication with the first access port, and the other one thereof is placed in fluid communication with the second access port, and a second position wherein one of the second filter port and the second hose port is placed in fluid communication with the first access port, and the other one thereof is placed in fluid communication with the second access port.
A method of imaging and analyzing the joint of a patient, such as a knee, involves acquiring a three-dimensional data of the joint of the patient, reconstructing an articular contact geometry of the joint based on the 3D data, determining a tissue quality on articular contact geometry based on the 3D data, determining movement capacity of the joint based on the reconstructed articular contact geometry; and determining a motion signature of the joint based on the reconstructed articular contact geometry and the tissue quality.
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (Israël)
HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (Israël)
THE CLEVELAND CLINIC FOUNDATION (USA)
Inventeur(s)
Blum, Galia
Gastman, Brian
Abd-Elrahman, Ihab
Khairi, Noha
Ben Yehuda, Dina
Gutman, Miri
Perlman, Riki
Sinai-Turyansky, Reut
Abrégé
The present invention is directed to cathepsin inhibitor conjugates, precursors and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with abnormal cathepsin activity in a subject in need thereof are also provided.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compositions thereof, utilized for treating for example, kidney disease, diabetes and cardiovascular disease, disorders that are associated with inhibiting the conversion of choline to trimethylamine.
A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
C07C 69/52 - Esters d'acides acycliques carboxyliques non saturés dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique
C07C 69/608 - Esters d'acides carboxyliques avec un groupe carboxyle lié à un atome de carbone acyclique et comportant un cycle autre qu'un cycle aromatique à six chaînons dans la partie acide
C07C 211/02 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé acyclique
C07C 215/08 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique avec un seul groupe hydroxy et un seul groupe amino liés au squelette carboné
77.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE
Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compositions thereof, utilized fortreating for example, kidney disease, diabetes and cardiovascular disease, disorders that are associated with inhibiting the conversion of choline to trimethylamine.
A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
C07C 69/52 - Esters d'acides acycliques carboxyliques non saturés dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique
C07C 271/08 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques
C07C 309/03 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
C07C 311/03 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant les atomes d'azote des groupes sulfonamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C07C 311/08 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
78.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE
Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compositions thereof, utilized for treating for example, kidney disease, diabetes and cardiovascular disease, disorders that are associated with inhibiting the conversion of choline to trimethylamine.
The present invention relates to methods, compositions, systems, and kits for the analysis of hydrogen sulfide using an 34S isotope-labeled sulfide compound (e.g., 34S isotope-labeled sodium sulfide), a reducing agent and derivatization reagent, in particular by isotope dilution mass spectrometry.
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01J 3/00 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur
G01N 21/3504 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse des gaz, p. ex. analyse de mélanges de gaz
Disclosed herein are compounds that inhibit the function of 3β-hydroxysteroid dehydrogenase (3βHSD1), pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., for the treatment of prostate cancer, breast cancer, and other diseases dependent on the activity of 3βHSD1.
The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker or "ARB") (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the eye condition is selected from: i) a comeal scarring fibrosis, ii) a transforming growth factor beta-induced (TGFBI) comeal dystrophy, iii) a conjunctival fibrotic disease, iv) an intraocular fibrotic disease, and v) a conjunctival bleb scarring and/or shunt encapsulation (e.g., following glaucoma surgery).
An immunostimulatory nanoparticle comprising a biocompatible lipid shell that defines an outer surface of the nanoparticle and a core, which is loaded with a Toll-like Receptor 9 (TLR9) agonist and a nucleic acid inhibitor of V domain Immunoglobulin Suppressor of T cell activation (VISTA), and optionally a plurality of targeting moieties linked to the outer surface, wherein the optional targeting moieties are configured to direct the nanoparticle to tumor-resident myeloid cells in a tumor microenvironment upon administration of the nanoparticle to a subject with cancer.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A bone tissue collection device is provided with an exterior collection container and a porous interior filter container. The device includes a lid having an upper face and is configured to releaseably seal the exterior collection container and interior filter container. A suction inlet tube and a suction outlet tube are operably coupled to the lid and angled from the upper face of the lid.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
84.
SYSTEMS AND METHODS FOR AUTOMATED LESION DETECTION USING MAGNETIC RESONANCE FINGERPRINTING DATA
Systems and methods for automated lesion detection are provided. Quantitative maps of tissue properties may be generated from magnetic resonance fingerprinting (MRF) data and may be used with a z-score determination and a trained lesion detection classifier for automated epilepsy lesion detection. In some configurations, lesion detection may be performed at an individual-level with MRF data associated with a subject that includes a detectable lesion.
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Provided herein are composition, systems, kits, and methods for preventing and/or treating, reversing, and/or inhibiting progression of, a neurodegenerative and/or neurological conditions and/or eye conditions (e.g., retinitis pigmentosa) by administering a plurality of nanoparticles to a subject via subcutaneous, intramuscular, or intraperitoneal injection such that the plurality of nanoparticles are taken up by lymphatic capillaries and are transported to neurological and/or eye tissue of the subject via the subject's lymphatic system, wherein the plurality of nanoparticles encapsulate, or are attached or absorbed to, at least one drug agent.
A cannula, system, and method for de-airing a patient's heart following surgery are described. The cannula includes a tubular wall having a distal end portion and a proximal end portion. The wall also has a length extending from the distal end portion to the proximal end portion. The wall at least partially defines a first lumen extending lengthwise of the wall into the distal end portion and terminating in a closed first end. The wall also at least partially defines a second lumen extending lengthwise of the wall and terminating in a closed second end. The wall is configured and dimensioned such that the cannula can be inserted into the patient's heart. A first aperture extends through the wall from the first lumen to an exterior surface of the wall. A second aperture extends through the wall from the second lumen to the exterior surface of the wall.
A method for optimization of spine screw placement in a spine of a patient. The method includes a) for a first entry point, defining a first plurality of primary rays; b) eliminating each of the first plurality of primary rays that intersects a boundary of one or more vertebrae of the spine model; c) defining a plurality of parallel rays disposed circumferentially around, and extending parallel to, the associated primary ray at a predetermined radius therefrom; d) iteratively adjusting a length of the plurality of parallel rays associated with each of the first set of optimized screw trajectories until an optimized length is determined; e) presenting a list of the first set of optimized screw trajectories for the first entry point; and f) implanting a spine screw in a vertebra of the patient corresponding to a selected one of the first set of optimized trajectories.
An apparatus for at least partially repairing a regurgitant heart valve includes at least one subvalvular device defining a longitudinal axis and including a subvalvular portion located adjacent a subvalvular cardiac wall adjacent to the heart valve. An anchor portion is adjacent to, and is longitudinally spaced from, the subvalvular portion. A connector neck is interposed longitudinally between, and is attached to both of, the subvalvular portion and the anchor portion. The connector neck penetrates longitudinally through at least one of a base of the first valve leaflet and an annulus of the heart valve at a manufactured puncture site. A fastener is selectively connected to the at least one subvalvular device. The fastener penetrates through at least one of the first and second valve leaflets to maintain the at least one leaflet in a predetermined position with respect to the at least one subvalvular device.
A method includes receiving with a controller, neurophysiology activity data; receiving with the controller, biometric data for the patient; identifying with the controller, one or more weighted components of the neurophysiology activity data; assigning with the controller, based on the biometric data for the patient, a weight to each of the one or more weighted components; determining with the controller, based on a trained algorithm applied to the one or more weighted components, whether to apply the DBS; and instructing application with the controller, based on the determination, the DBS.
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Marasco, Paul, D.
Schofield, Jonathon, S.
Shell, Courtney, E.
Thumser, Zachary, C.
Beckler, Dylan
Sakai, Jonathan
Abrégé
A cognitive illusion of ownership over a proxy extremity (e.g. a hand) is provided by discordant touch and visual information to a user. While the user feels the touch on their real extremity, they see a corresponding touch on the proxy extremity. The user's internally modeled reality is then updated to move the felt location of the real extremity to the seen location of the proxy extremity. As a result, the user embodies the proxy extremity, thereby disembodying the real extremity. Pain associated with medical procedures performed on the real extremity is then mitigated. And because an epileptic brain is less stringent when resolving conflict between what is seen and what is felt, correlations in time or space can shift attribution of the sensation of the felt touch on the user's real extremity to the location of the proxy extremity. This can be helpful in treating and/or diagnosing epilepsy.
A61M 21/00 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscienceDispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p. ex. pour mettre en état d'hypnose
92.
MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE
The present disclosure provides compositions and polynucleotides for increasing expression of an immunogenic and/or antigenic polypeptide (e.g., in a vaccine). The disclosure further provides methods of using the disclosed compositions, polynucleotides, and vaccines for the treatment of diseases and disorders (e.g., infections). The compositions and polynucleotides include a first nucleic acid encoding a viral regulatory protein and a second nucleic acid encoding an immunogenic polypeptide, wherein the immunogenic polypeptide is codon-optimized to a vims from which the regulatory protein is derived.
The present invention relates to compositions, systems, and methods for treating a subject with a corneal injury and/or an existing corneal scar using a composition comprising an ACE-2 receptor antagonist (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the ACE-2 receptor antagonist is present in the composition at a concentration of about 0.2 mg/ml to 0.9 mg/ml or about 0.1 mg/ml to 2.0 mg/ml.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Damaser, Margot S.
Majerus, Steve
Abdelhady, Mohamed
Abrégé
To perform urological diagnostics of a patient, detrusor pressure can be estimated using bladder pressure recordings from a single sensor. A signal comprising the bladder pressure data recorded by the sensor can be received. The bladder pressure data can include at least a detrusor pressure data component and a corrupting data component. An estimate of the corrupting data component can be extracted from the bladder pressure data. The detrusor pressure of the patient can be estimated based on the estimate of the corrupting data component and/or the estimate of the detrusor pressure data. An output indicative of the detrusor pressure of the patient can be provided based on the estimate of the detrusor pressure data component.
Systems and methods for sonicating a body within an organ of a patient include supplying ultrasound energy to the body in order to produce a liquified material, which can then be aspirated from the body via a catheter. Image guidance is used during aspiration of the liquified material.
A61B 90/10 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 90/11 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
96.
OBJECT COUNTING SYSTEM USING CONVOLUTIONAL NEURAL NETWORK FOR MEDICAL PROCEDURES
The present disclosure relates to a system and method for recognizing objects used in a medical procedure using a convolutional neural network. No database of image information for such objects is used or required. Rather, the neural network is trained to recognize the objects, and does not require any such image database. The system is able to reconcile the recognized objects against a 'counted-in' list of objects for the procedure, to ensure that all such objects are accounted for prior to closing the procedure.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/143 - Détection ou éclairage à des longueurs d’onde différentes
97.
METABOLIC AND INFLAMMATORY MARKERS FOR CAR-T CELL THERAPY
The present invention relates to CAR T cell-independent and dependent metabolic and inflammatory biomarkers of CRS, ICANS, CAR T cell expansion and patient survival, that can be used to predict patient response, enable mitigating strategies for toxicities in the clinic and improve patient outcomes and survival.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
Disclosed herein are compounds that inhibit the 3C-like protease of SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral infection, such as a coronavirus infection.
C07D 403/00 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
99.
NON-CONTACT LITHOTRIPSY USING PHOTONIC NANOPARTICLES
Methods of non-contact lithotripsy are disclosed, wherein photonic nanoparticles are delivered in the vicinity of kidney stones, e.g. within a kidney. The nanoparticles then are irradiated with non-ionizing electromagnetic radiation to activate the nanoparticles and fragment the stone. In preferred embodiments, the nanoparticles are placed effectively into contact with the kidney stone, via functionalizing the particles with ligands that will adhere to the known or anticipated chemical composition of the stone surface. A combination of a kidney stone and a photonic nanoparticle in its vicinity or adhered thereto at its surface also is disclosed.
A61B 18/26 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet pour produire une onde de choc, p. ex. lithotritie par laser
A61B 18/20 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61B 18/28 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet pour chauffer une sonde thermique ou un matériau absorbant thermique
A61N 5/067 - Thérapie par radiations utilisant un rayonnement lumineux utilisant un rayonnement laser
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A bronchial stent includes a first branch configured to widen, open, and/or mechanically support a first airway; an obstructive portion that, when the stent is deployed in the first airway, obstructs a second airway, the second airway forming a branching connection with the first airway; and a feature proximal to the obstructive portion, the feature configured to facilitate opening of the obstructive portion.
A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents
A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical
A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
brevets
